Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate

J Pediatr Hematol Oncol. 2004 May;26(5):320-2. doi: 10.1097/00043426-200405000-00013.

Abstract

This article reports early blastic transformation of chronic myeloid leukemia (CML) in a child following a complete cytogenetic response induced by imatinib mesylate. A 14-year-old Japanese boy was diagnosed with t(9;22) cryptic CML in the chronic phase and treated with imatinib. His response to treatment was slow, but a major cytogenetic response was obtained at 142 days of therapy. However, he developed lymphoid blastic transformation at 9 months. He attained remission with acute lymphoblastic leukemia-type chemotherapy and then successfully received a non-T-cell-depleted allogeneic stem cell transplantation (allo-SCT) with his mother's two loci-mismatched donor cells. A sudden blastic transformation may occur even with a complete cytogenetic response induced by imatinib. CML patients who respond slowly to imatinib may still be candidates for allo-SCT, even when a major cytogenetic response is obtained.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Benzamides
  • Blast Crisis / etiology
  • Blast Crisis / therapy*
  • Cytogenetic Analysis
  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation
  • Histocompatibility
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Leukemia, Myeloid, Chronic-Phase / therapy
  • Lymphocyte Activation*
  • Male
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Recurrence
  • Remission Induction / methods
  • Transplantation, Homologous

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate